IDH1 and central nervous system cancer: We and others have shown that TERT promoter mutations are frequently observed (> 90%) in oligodendrogliomas with mutant IDH and 1p/19q codeletion, and that the presence of TERT promoter mutations is associated with favorable outcomes in IDH-mutated gliomas [6, 14, 15].